Statin and mortality in COVID-19: a systematic review and meta-analysis of pooled adjusted effect estimates from

Related Experiment Video

Updated: Oct 31, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.8K

Ahmad Fariz Malvi Zamzam Zein1,2, Catur Setiya Sulistiyana3, Uswatun Khasanah4

  • 1Department of Internal Medicine, Faculty of Medicine, Universitas Swadaya Gunung Jati, Cirebon, Jawa Barat, Indonesia fariz_zein_dr@yahoo.com.

Postgraduate Medical Journal
|July 1, 2021
PubMed

Insights

Statin use was associated with a significant reduction in mortality for patients with COVID-19. This meta-analysis of propensity-score matched studies confirms statins

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Epidemiology

Background:

  • Statin use in COVID-19 patients may improve outcomes but is often confounded by comorbidities.
  • Propensity-score matching (PSM) and adjusted analyses are crucial for unbiased evaluation.

Purpose of the Study:

  • To investigate the association between statin use and mortality in COVID-19 patients.
  • To pool adjusted effect estimates from PSM-matched studies and randomized controlled trials to minimize bias.

Main Methods:

  • Systematic literature search of PubMed, Scopus, and Embase up to March 1, 2021.
  • Inclusion of studies using PSM with Inverse Probability Treatment Weighting or multivariable regression.
  • Meta-analysis of eight PSM-matched studies involving 14,446 patients.

Main Results:

  • Statin use was linked to decreased COVID-19 mortality (RR 0.72; 95% CI 0.55-0.95).
  • In-hospital statin administration also showed reduced mortality (RR 0.71; 95% CI 0.54-0.94).
  • No significant impact of age, male gender, diabetes, or hypertension on this association was observed.

Conclusions:

  • This meta-analysis demonstrates that statin use decreases mortality risk in COVID-19 patients.
  • Adjusted analyses in PSM-matched cohorts support the protective effect of statins against COVID-19 mortality.
Abstract

Keywords:
COVID-19cardiologyclinical pharmacology

More Related Videos

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

833

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
69
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
431
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
609
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
58
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
85